← All trials
NCT04600921
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 24, 2021
- Primary completion
- Dec 30, 2023
- Completion date
- Jan 6, 2024
- First posted
- Oct 23, 2020
- Last posted
- Sep 24, 2021
- Enrollment
- 402
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical University of GrazLead sponsor
- Johannes Kepler UniversityCollaborator
- Medical University of ViennaCollaborator
- Medical University of GrazOverall official - principal investigator
- Medical University InnsbruckCollaborator
- KH Elisabethinen LinzCollaborator
- Klinik OttakringCollaborator
- Klinikum KlagenfurtCollaborator
- Klinikum Wiener NeustadtCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.